Lecanemab and Vascular-Amyloid Deposition in Brains of People With Down Syndrome
These findings suggest significant binding of lecanemab to cerebral amyloid angiopathy in DS. Lecanemab should be rigorously tested in clinical trials for AD in the DS population to determine its safety and efficacy, especially in those older than 43 years.
Authors
- Michael B. Miller (ORCID: https://orcid.org/0000-0002-6205-3314)
- Adam M. Brickman (ORCID: https://orcid.org/0000-0002-5125-8226)
- Donna M. Wilcock (ORCID: https://orcid.org/0000-0003-3388-1564)
- Frederick A. Schmitt (ORCID: https://orcid.org/0000-0003-4315-2488)
- Elizabeth Head (ORCID: https://orcid.org/0000-0003-1115-6396)
- Jordan P. Harp (ORCID: https://orcid.org/0000-0003-2089-0883)
- Jesse R. Pascual (ORCID: https://orcid.org/0000-0002-3307-0887)
- Dennis J. Selkoe (ORCID: https://orcid.org/0000-0001-8846-9767)
- Jasmeer P. Chhatwal (ORCID: https://orcid.org/0000-0002-7792-1698)
- Ira T. Lott (ORCID: https://orcid.org/0000-0002-3107-0752)
- Lei Liu (ORCID: https://orcid.org/0000-0002-9995-9080)
- Adriana Saba
- Elizabeth L. Hennessey
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- University of Kentucky (US)
- University of California, Irvine (US)
- Massachusetts General Hospital (US)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
- Columbia University (US)
Publication Details
- Journal
- JAMA Neurology
- Published
- 2024-08-19
- DOI
- https://doi.org/10.1001/jamaneurol.2024.2579
- Citations
- 17
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.55